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RECEIVED 
 
We report the syntheses of combretastatins D-2 and D-4, as well as a formal synthesis of combretastatin 
D-1 by a conceptually new route harnessing a ring-contracting flash vacuum pyrolytic extrusion of 
sulfur dioxide from the respective 16-membered sulfone precursors. Via flash vacuum pyrolysis even 
metaparacyclophanes as small and strained as the hitherto unknown oxa[1.5]metaparacyclophane could 
be prepared as a side product en route to combretastatin D-2 by synchronous extrusion of SO2 and CO2. 
Keywords: Combretastatin D, diaryl ether heptanoid, oxa[1.5]metaparacyclophane, flash vacuum 
pyrolysis. 
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Introduction 
Naturally occurring cyclic diaryl ether heptanoids (DAEH)1 share an oxa[1.7]metaparacyclophane 
scaffold while differing in the nature and position of additional functional groups on the n-heptyl spacer 
and the phenyl rings. The high incidence of biological activity2 among these plant metabolites, their 
challenging structures, and their potential chirality originating from a restricted conformational 
flexibility3 attracted the interest of organic chemists. Figure 1 shows typical examples of natural DAEH: 
the longest known optically active acerogenin A 14 and the optically inactive diene tedarene A 2.5 The 
combretastatins D constitute a particulary interesting subclass of DAEH, both chemically and with 
respect to their biological activity.6 They are metabolites of various Combretaceae species which feature 
a lactone group as part of the 7-atom tether. The epoxy macrolide (–)-combretastatin D-1 3 and its 
deoxygenated congener combretastatin D-2 4 were isolated from the South-African bushwillow 
Combretum caffrum and were structurally elucidated in the late 1980s by Pettit et al.7 They were found 
to interfere with the dynamics of the polymerization of tubulin in cells by stabilizing the microtubules, 
in contrast to the stilbene-like combretastatins A which stabilize the tubulin heterodimers and inhibit 
their polymerization.8 Pettit et al. also reported antiproliferative activities of combretastatin D-2 with 
single-digit micromolar IC50 values against various cancer cell lines.9 The saturated analogue 
combretastatin D-4 5 was isolated from the stem of Getonia floribunda (Combretaceae), characterized, 
and found inactive in all biological tests by Vongvanich et al.10 The same compound was later isolated 
by Ponnapalli et al. from the Mangrove shrub Aegeceras corniculatum (Aegecerataceae) and termed 
corniculatolide A.11 No specific optical rotations were reported of combretastatins D-2 and D-4. The 
known synthetic approaches to the combretastatins D differ by the ring closure reaction and by the 
method and timing of the introduction of the alkene or epoxide, respectively. The first synthesis of 
combretastatin D-2 4 by Boger et al.12 employed an Ullmann coupling for the cyclization and a Still-
Gennari olefination to introduce the (Z)-alkene. The groups of Deshpande13 and Couladouros14 closed 
the macrocycle by means of a Mitsunobu lactonization under high-dilution conditions which gave high 
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yields only when preceding the introduction of the alkene. Mann et al. used a (Z)-selective Wittig 
olefination to close the ring of 4.15 Combretastatin D-1 3 was synthesized by Rychnovsky et al. and 
Couladouros et al. by a Mitsunobu macrolactonization followed by introduction of the epoxide, either 
via epoxidation16 of an alkene with mCPBA or enantioselectively with a Jacobsen catalyst, or via 
dehydration17 of a vicinal diol. The macrocycle of combretastatin D-4 5 was closed in previous 
syntheses by the groups of Imoto18, Reddy,19 and Pettit9 either via Mitsunobu lactonization or Ullmann 
coupling. 
Because of our interest in antimitotic agents and the combretastatins in particular, we now developed a 
conceptually new approach to the combretastatins D that generates the 15-membered ring via 
contraction of a macrocyclic sulfone precursor by flash vacuum pyrolysis (FVP).   
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Figure 1. Structures of diaryl ether heptanoids. 
Results and Discussion 
Initially, we intended to contract 16-membered sulfone derivatives of the respective combretastatins D 
by extrusion of sulfur dioxide according to the Ramberg-Baecklund protocol.20 Although all attempts to 
initiate this reaction failed, the sulfone precursors turned out to undergo the desired ring contraction 
when submitted to a flash vacuum pyrolysis under carefully adjusted conditions. Scheme 1 shows the 
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synthesis of sulfone 14, the precursor leading up to combretastatin D-2 4. 4-Bromobenzaldehyde 6 was 
converted to the (Z)-bromocinnamate 7 by a HWE reaction with the anion of an Ando ester phosphonate 
in near quantitative yield.21 Reduction of this ester with DIBAL-H afforded the (Z)-bromocinnamyl 
alcohol 8 which was submitted to a copper-mediated Ullmann coupling22 to give the corresponding 
diphenyl ether 9 in 57% yield. Steglich-Hassner esterification23 of the alcohol 9 with S-acetylthioacetic 
acid furnished aldehyde 10 which was reduced to the benzyl alcohol 11 with sodium borohydride.24 
Deacetylation25 of 11 with hydrazine liberated the thiol 12 which underwent an intramolecular 
thioetherification to give macrolide 13 when treated with sulfuric acid in acetonitrile. Quantitative 
oxidation with mCPBA eventually afforded sulfone 14.26 
SCHEME 1.a Synthesis of Sulfone 14, a Precursor to Combretastatin D-2. 
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a Reagents and conditions: (i) (PhO)2P(O)CH2CO2Me, KOtBu, THF, !78 °C, 2 h; (ii) DIBAL-H, 
CH2Cl2, –78 °C, 1 h; (iii) isovanillin, CuI, Cs2CO3, N,N-dimethylglycine, 1,4-dioxane, reflux, 24 h; (iv) 
S-acetylthioacetic acid, EDC, DMAP, CH2Cl2, rt, 3 h; (v) NaBH4, 20% MeOH/THF (1:1), rt, 5 min; (vi) 
H2NNH2, MeCN, rt, 2 h; (vii) H2SO4, MeCN, 0 °C, 30 min; (viii) mCPBA, CH2Cl2, 0 °C ! rt, 2 h. 
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Sulfone 20, the saturated congener of 14 and precursor to combretastatin D-4 5, was obtained 
analogously starting with the PtO2-catalyzed hydrogenation of the more readily available (E)-isomer of 
9 (cf the Supporting Information) (Scheme 2).  
SCHEME 2.a Synthesis of Sulfone 20, a Precursor to Combretastatin D-4. 
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a Reagents and conditions: (i) PtO2, MeOH, H2 (1 bar), rt, 15 min; (ii) S-acetylthioacetic acid, EDC, 
DMAP, CH2Cl2, rt, 3 h; (iii) NaBH4, 20% MeOH/THF (1:1), rt, 5 min; (iv) H2NNH2, MeCN, rt, 2 h; (v) 
H2SO4, MeCN, 0 °C, 30 min; (vi) mCPBA, CH2Cl2, 0 °C ! rt, 2 h, 98%. 
A formal synthesis of combretastatin D-1 3 was achieved by first establishing the macrolide by 
extrusion of SO2 from a cyclic sulfone precursor containing a protected, appropriately configured syn-
diol (Scheme 3). The diol was obtained by first protecting27 the alcohol (E)-9 as the pivalate 21 which 
was dihydroxylated according to Sharpless28 with ADmix-ß to afford pure syn-diol 22 in almost 60% 
yield and > 99% ee as to chiral HPLC. The hydroxy groups were protected29 as TIPS ethers to give ester 
23 which was reduced to the diol 24 with DIBAL-H. Selective oxidation with MnO230 afforded the 
hydroxyaldehyde 25 which was esterified with S-acetylthioacetic acid to give aldehyde 26. The latter 
was reduced quantitatively to the benzylalcohol 27 which was deacetylated with hydrazine to leave the 
thiol 28 in 94% yield. Finally, a new mild macrocyclization protocol employing SO3 • pyridine31 instead 
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of sulfuric acid afforded the thioether 29 which was oxidized to the cyclic sulfone 30 with mCPBA.     
SCHEME 3.a Synthesis of Sulfone 30, a Precursor to Combretastatin D-1. 
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a Reagents and conditions: (i) PivCl, CH2Cl2, 40 °C, 20 h; (ii) ADmix-ß, MeSO2NH2, tBuOH/H2O (1:1), 
3 °C, 28 h; (iii) TIPSOTf, 2,6-lutidine, DMF, 60 °C, 27 h; (iv) DIBAL-H, CH2Cl2,  
–78 °C, 1 h; (v) MnO2, CHCl3, rt, 22 h; (vi) S-acetylthioacetic acid, EDC, DMAP, CH2Cl2, rt, 18 h; (vii) 
NaBH4, 20% MeOH/THF (1:1), rt, 10 min; (viii) H2NNH2, MeCN, rt, 2 h; (ix) SO3•py, toluene, 111 °C, 
8 h; (x) mCPBA, CH2Cl2, 0 °C ! rt, 2 h, 83%. 
The cyclic sulfones 14, 20, and 30 were then subjected to various modifications of the Ramberg-
Baecklund reaction, however, to no avail. In contrast, their flash vacuum pyrolysis32,33 under carefully 
adjusted conditions led to the extrusion of SO2 with formation of the 15-membered combretastatin D 
skeleton. Extrusion of SO2 using flash vacuum pyrolysis has been widely used in classic synthetic 
approaches to cyclophanes34 but the targets in these studies were typically hydrocarbons with no 
sensitive functional groups present. For all three compounds 14, 20, and 30, 600 °C was found to be the 
optimum temperature, with 550 °C and lower temperatures giving partly unchanged starting material, 
and values of 625 °C and higher leading to increased decomposition and in the case of 14 to increased 
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formation of 35 at the expense of the desired product 34. The sterically least hindered sulfone 20 
afforded the ring-contracted macrolide 31 in 53% yield when submitted to a FVP at 600 °C and 5 " 10–2 
Torr. It was demethylated with AlCl3/EtSH16 to give combretastatin D-4 5 in 96% yield (Scheme 4). The 
FVP of sulfone 30 bearing two bulky OTIPS groups also furnished the corresponding macrolide 32 
albeit in only 30% yield. Deprotection of 32 with aqueous HF afforded the diol 33 in 53% yield. To 
complete the synthesis of combretastatin D-1 the diol 33 would have to be demethylated with 
AlCl3/EtSH and converted to the target epoxide by dehydration according to Couladouros et al.17 For 
sulfone 14, void of bulky groups and featuring a Z-alkene that might confer some rigidity and pre-
orientation for the SO2 extrusion, we expected a smoothly proceeding FVP. What we actually found 
upon FVP of sulfone 14 was a separable mixture of the expected macrolide 34 (20%), which was 
demethylated with AlCl3/EtSH to give combretastatin D-2 4, and of the first ever 
oxa[1.5]metaparacyclophane 35 (6%), originating from a concomitant extrusion of SO2 and CO2. A 
single crystal X-ray diffraction analysis of 35 showed that the two phenyl rings were oriented almost 
perpendicular to each other, with the isolated H-atom of the trisubstituted phenyl ring located 
perpendicular to the center of the disubstituted phenyl ring at a remarkably short distance of 2.28 Å 
(Fig. 2). The structure of 35 in solution probably does not deviate much from its crystal structure since 
in the 1H NMR spectrum of 35 this H-atom resonates at a conspicuous high-field shift of 4.08 ppm.     
 
8 
SCHEME 4.a Flash Vacuum Pyrolysis of Sulfones 14, 20, and 30. 
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a Reagents and conditions: (i) Flash vacuum pyrolysis, 600 °C, 5 " 10–2 Torr; (ii) AlCl3, EtSH, CH2Cl2, 
!17 °C, 1 h; (iii) HF(aq), THF, rt, 3 d. 
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Figure 2. Molecular structure of oxa[1.5]metaparacyclophane 35, as thermal ellipsoid representations at 
50% probability level showing the atomic numbering schemes (H-atoms omitted). CCDC 1505171. 
Selected bond lengths [Å] and angles [°]: O2–C11 1.408(6), O2–C13 1.426(6), C1–C2 1.330(9), C1–
C16 1.492(8), C5–C6 1.515(7), O2–C11–C9 117.6(4), O2–C11–C12 123.6(4), C5–C6–C12 121.3(4), 
O2–C13–C14 117.9(5), O2–C13–C18 118.3(5), O2–C13–C18–C17 151.6(5), O2–C13–C14–C15 
151.4(5), C1–C16–C17–C18 –154.2(5), C16–C1–C2–C3 –2.1(9), C1–C2–C3–C4 94.6(7). 
Conclusions 
The combretastatins D-1, D-2, and D-4 were synthezised by a conceptually new route harnessing a ring-
contracting flash vacuum pyrolytic extrusion of sulfur dioxide from the respective 16-membered sulfone 
precursors. The latter were obtained by an intramolecular thiol benzylation followed by an oxidation of 
the resulting thioether. Via flash vacuum pyrolysis even the oxa[1.5]metaparacyclophane 35 could be 
prepared as a side product en route to combretastatin D-2 by synchronous extrusion of SO2 and CO2. 
The mechanism of this process as well as the chemistry and potential chirality of such diaryl ether 
pentanoids (DAEP) remain to be elucidated.  
 
 
10 
Experimental Section 
General Remarks. All moisture or air sensitive reactions were performed in oven-dried glassware 
under an argon atmosphere using standard Schlenk techniques. IR spectra were recorded with an FT-IR 
spectrophotometer equipped with an ATR unit. Melting Points were determined with a Büchi M-565 
melting point apparatus and are uncorrected. Chemical shifts of NMR signals are given in parts per 
million (!) downfield from tetramethylsilane for 1H and 13C NMR spectra. Mass spectra were obtained 
under EI (70 eV) conditions. High resolution mass spectra were obtained with a UPLC/Orbitrap MS 
system in ESI mode. For chromatography silica gel 60 (230-400 mesh) was used. Flash vacuum 
pyrolysis (FVP) was carried out in a conventional flow system by subliming the starting material 
through a horizontal quartz tube (30 " 2.5 cm) externally heated by a tube furnace to 600 °C and 
maintained at a pressure of 5 " 10–2 torr by a rotary vacuum pump. Products were collected in a liquid 
N2 cooled U-shaped trap and purified as noted.  
Methyl (Z)-4-Bromocinnamate 7. A solution of (PhO)2P(O)CH2CO2Me35 (11.4 g, 37.2 mmol) in dry 
THF (315 mL) was treated with KOtBu (5.01 g, 44.7 mmol) at !78 °C for 15 min under an inert gas 
atmosphere. p-Bromobenzaldehyde 6 (6.25 g, 33.8 mmol) was added and the mixture was stirred at !78 
°C. After 2 h the reaction mixture was quenched with saturated aqueous NH4Cl (20 mL) and diluted 
with EtOAc (30 mL). After separation of the layers the aqueous phase was extracted three times with 
EtOAc (20 mL). The combined organic phases were washed with brine and dried over anhydrous 
Na2SO4. The volatiles were removed under reduced pressure and the crude product was purified by 
column chromatography (cyclohexane/EtOAc 5:1) to yield 7 (7.91 g, 32.8 mmol, 97%) as colorless 
crystals of mp 41–44 °C [lit.36 40–42 °C]; Rf = 0.66 (cyclohexane/EtOAc 3:1). IR (ATR) #max 2950, 
1721, 1632, 1587, 1488, 1439, 1197, 1168, 1072, 1011, 844, 819 cm!1; 1H NMR (CDCl3, 500 MHz) ! 
3.71 (s, 3 H), 5.98 (d, J = 12.7 Hz, 1 H), 6.88 (d, J = 12.7 Hz, 1 H), 7.47–7.50 (m, 4 H); 13C NMR 
(CDCl3, 125 MHz) ! 51.5, 119.9, 123.4, 131.2, 131.4, 133.5, 142.3, 166.3; MS (EI) m/z (%) 242 (54), 
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240 (56) [M]+, 211 (87), 209 (88), 183 (35), 181 (37), 102 (100), 75 (26), 51 (31). 
(Z)-4-Bromocinnamyl alcohol 8. A solution of ester 7 (9.20 g, 38.3 mmol) in CH2Cl2 (72 mL) was 
cooled to !78 °C and treated dropwise with DIBAL-H (1M in hexane, 84.2 mL, 84.2 mmol). After 1 h 
the reaction mixture was quenched with MeOH (20 mL) and the formed Al(OH)3 precipitate was 
carefully dissolved by addition of 1M aqueous HCl solution (100 mL). The reaction mixture was 
allowed to warm to room temperature and the layers were separated. The aqueous phase was extracted 
with CH2Cl2 (2 " 100 mL). The combined organic phases were washed with brine (100 mL), dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was crystallized from 
hexane to afford 6.62 g of 8 (31.1 mmol, 81%) as colorless crystals of mp 69–71 °C [lit.9 69.3–70.6 °C]; 
Rf 0.38 (cyclohexane/EtOAc 3:1). IR (ATR) #max 3239, 3016, 1488, 1388, 1323, 1114, 1077, 1026, 
1005, 974, 943, 835, 791, 671 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.57 (t, J = 5.5 Hz, OH), 4.36–4.42 
(m, 2 H), 5.90 (dt, J = 11.8, 6.5 Hz, 1 H), 6.50 (d, br, J = 11.8 Hz, 1 H), 7.05–7.11 (m, 2 H), 7.44–7.49 
(m, 2 H); 13C NMR (CDCl3, 125 MHz) ! 59.5, 121.3, 130.0, 130.3, 131.4, 131.8, 135.3; MS (EI) m/z 
(%) 214 (88), 212 (90) [M+], 171 (80), 169 (78), 158 (28), 156 (30), 133 (100), 115 (51), 104 (38), 91 
(63), 77 (43), 66 (25), 55 (31), 51(33). 
(Z)-3-[4-(3-Hydroxyprop-1-en-1-yl)phenoxy]-4-methoxybenzaldehyde (Z)-9. A solution of alcohol 8 
(3.74 g, 17.6 mmol) and isovanillin (4.00 g, 26.3 mmol) in 1,4-dioxane (13.4 mL) was treated with 
Cs2CO3 (11.4 g, 35.1 mmol), CuI (334 mg, 1.76 mmol), and dimethylglycine hydrochloride (544 mg, 
5.27 mmol). The resulting suspension was stirred at 101 °C for 24 h, cooled, and treated with ethyl 
acetate (50 mL). The organic phase was washed with brine (50 mL), the aqueous phase was extracted 
with ethyl acetate (3 " 50 mL), and the combined organic layers were dried over anhydrous Na2SO4. 
The volatiles were removed under reduced pressure and the remaining crude was purified by column 
chromatography (cyclohexane/ethyl acetate 3:1) to yield (Z)-9 (2.84 g, 9.99 mmol, 57%) as a light 
yellow oil of Rf 0.38 (cyclohexane/ethyl acetate 1:1). IR (ATR) #max 3349, 2844, 1683, 1598, 1578, 
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1503, 1432, 1273, 1220, 1163, 1119, 1012, 813, 637 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.67 (s, br, 
OH), 3.94 (s, 3 H), 4.43 (dd, J = 6.5, 1.3 Hz, 2 H), 5.84 (dt, J = 11.7, 6.5 Hz, 1 H), 6.52 (d, J = 11.7 Hz, 
1 H), 6.91–6.97 (m, 2 H), 7.11 (d, J = 8.4 Hz, 1 H), 7.15–7.20 (m, 2 H), 7.47 (d, J = 2.0 Hz, 1 H), 7.67 
(dd, J = 8.4, 2.0 Hz, 1 H), 9.82 (s, 1 H); 13C NMR (CDCl3, 125 MHz) ! 56.3, 59.6, 112.1, 117.6, 119.8, 
128.3, 130.2, 130.25, 130.3, 130.5, 131.9, 146.0, 156.0, 156.3, 190.3; HRMS (ESI) m/z [M!H2O+H]+ 
calcd for C17H15O3+ 267.1016, found 267.1010. 
(E)-9. Analogously to the synthesis of (Z)-9, the isomer (E)-9 (5.94 g, 20.9 mmol, 80%) was obtained as 
a colorless oil from (E)-4-bromocinnamyl alcohol17b (5.61 g, 26.3 mmol), isovanillin (6.00 g, 
39.4 mmol), Cs2CO3 (17.1 g, 52.6 mmol), CuI (0.50 g, 2.63 mmol) and dimethylglycine hydrochloride 
(0.82 g, 7.88 mmol). Rf 0.12 (cyclohexane/ethyl acetate 2:1). IR (ATR) #max 3502, 2843, 1671, 1598, 
1580, 1506, 1435, 1402, 1264, 1228, 1172, 1123, 1088, 1012, 966, 854, 813, 790, 641, 632 cm!1; 1H 
NMR (CDCl3, 500 MHz) ! 1.51 (t, J = 5.9 Hz, OH), 3.95 (s, 3 H), 4.32 (td, J = 5.9 Hz, 1.4 Hz, 2 H), 
6.29 (dt, J = 15.9 Hz, 5.8 Hz, 1 H), 6.59 (d, J = 15.9 Hz, 1 H), 6.90–6.96 (m, 2 H), 7.11 (d, J = 8.4 Hz, 1 
H), 7.34–7.37 (m, 2 H), 7.45 (d, J = 2.0 Hz, 1 H), 7.67 (dd, J = 8.4 Hz, 2.0 Hz, 1 H), 9.82 (s, 1 H); 13C 
NMR (CDCl3, 125 MHz) ! 56.3, 63.8, 112.0, 118.2, 119.5, 127.7, 127.9, 128.2, 130.1, 130.3, 132.2, 
146.1, 156.2, 156.3, 190.4; HRMS (ESI) m/z [M!H2O+H]+ calcd for C17H15O3+ 267.1016, found 
267.1013. 
(Z)-3-[4-(5-Formyl-2-methoxyphenoxy)phenyl]allyl 2-acetylthioacetate 10. A mixture of alcohol 9 
(2.80 g, 9.84 mmol), CH2Cl2 (90 mL), S-acetylthioacetic acid37 (1.45 g, 10.8 mmol), EDC (2.08 g, 
10.8 mmol), and DMAP (602 mg, 4.94 mmol) was stirred for 3 h at room temperature and then washed 
with 0.1M citric acid (50 mL) and brine (100 mL), dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by column chromatography (cyclohexane/ethyl acetate 3:1) to 
yield 10 (2.65 g, 6.63 mmol, 67%) as a colorless oil. Rf 0.35 (cyclohexane/ethyl acetate 2:1). IR (ATR) 
#max 2957, 2844, 1738, 1686, 1598, 1578, 1504, 1432, 1394, 1273, 1221, 1155, 1119, 1110, 1016, 958, 
840, 815, 623 cm!1; 1H NMR (CDCl3, 500 MHz) ! 2.38 (s, 3 H), 3.73 (s, 2 H), 3.94 (s, 3 H), 4.89 (dd, 
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J = 6.8, 1.5 Hz, 1 H), 5.78 (dt, J = 11.7, 6.7 Hz, 1 H), 6.65 (d, J = 11.7 Hz, 1 H), 6.92–6.97 (m, 2 H), 
7.12 (d, J = 8.4 Hz, 1 H), 7.16–7.21 (m, 2 H), 7.49 (d, J = 2.0 Hz, 1 H), 7.69 (dd, J = 8.4, 2.0 Hz, 1 H), 
9.84 (s, 1 H); 13C NMR (CDCl3, 125 MHz) ! 30.1, 31.5, 56.3, 62.7, 112.2, 117.6, 120.4, 124.4, 128.3, 
130.25, 130.3, 131.1, 132.8, 145.7, 156.45, 156.5, 168.6, 190.2, 193.7; HRMS (ESI) m/zs [M+Na]+ 
calcd for C21H20NaO6S+ 423.0873, found 423.0866. 
(Z)-3-[4-(5-Hydroxymethyl-2-methoxyphenoxy)phenyl]allyl 2-acetylthioacetate 11. Aldehyde 10 
(1.53 g, 3.82 mmol) was dissolved in a 1:1 mixture of THF and 20% aqueous MeOH (52 mL). After 
addition of NaBH4 (72.0 mg, 1.91 mmol) the reaction mixture was stirred for 5 min at room 
temperature, quenched with water (30 mL) and diluted with ethyl acetate (30 mL). After separation of 
the layers the aqueous one was extracted with ethyl acetate (2 " 50 mL). The combined organic phases 
were washed with brine (100 mL), dried over Na2SO2, and concentrated under reduced pressure. The 
crude product was purified by column chromatography (cyclohexane/ethyl acetate 2:1, Rf 0.32) to yield 
11 (1.17 g, 2.90 mmol, 76%) as a colorless oil. IR (ATR) #max 3432, 1735, 1695, 1604, 1505, 1425, 
1270, 1223, 1163, 1124, 1025, 962 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.69 (t, br, J = 4.4 Hz, OH), 
2.38 (s, 3 H), 3.72 (s, 2 H), 3.83 (s, 3 H), 4.59 (d, J = 4.4 Hz, 2 H), 4.88 (dd, J = 6.7, 1.4 Hz, 2 H), 5.74 
(dt, J = 11.7, 6.7 Hz, 1 H), 6.63 (d, J = 11.7 Hz, 1 H), 6.88–6.94 (m, 2 H), 6.99 (d, J = 8.4 Hz, 1 H), 7.01 
(d, J = 2.1 Hz, 1 H), 7.11–7.18 (m, 3 H, 2-H); 13C NMR (CDCl3, 125 MHz) ! 30.1, 31.5, 56.1, 62.8, 
64.6, 112.8, 116.9, 120.2, 123.7, 123.9, 130.3, 130.1, 133.0, 134.1, 144.6, 150.9, 157.4, 168.6, 193.8; 
HRMS (ESI) m/z [M+Na]+ calcd for C21H22NaO6S+ 425.1029, found 425.1023. 
(Z)-3-[4-(5-Hydroxymethyl-2-methoxyphenoxy)phenyl]allyl 2-mercaptoacetate 12. A solution of 
thioester 11 (2.02 g, 5.00 mmol) in MeCN (140 mL) was treated with hydrazine solution (5.40 mL; the 
upper layer of a 1:3 mixture of hydrazine monohydrate and MeCN) and the resulting mixture was stirred 
at room temperature for 2 h. After dilution with CHCl3 (20 mL) the layers were separated and the 
organic phase was washed successively with 1M aqueous HCl (20 mL), saturated aqueous NaHCO3 
(20 mL), and brine (20 mL), then dried over Na2SO4 and concentrated under reduced pressure. The 
 
14 
crude product was purified by column chromatography (cyclohexane/ethyl acetate 3:1) to afford thiol 12 
(1.75 g, 4.86 mmol, 97%) as a colorless oil. Rf 0.19 (cyclohexane/ethyl acetate 2:1). IR (ATR) #max 
3420, 2935, 1729, 1603, 1583, 1504, 1441, 1424, 1267, 1219, 1167, 1121, 1022, 944, 839, 811, 750 
cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.74 (s, br, 1 H, OH), 2.01 (t, J = 8.2 Hz, 1H, SH), 3.28 (d, J = 8.2 
Hz, 2 H), 3.83 (s, 3 H), 4.59 (s, br, 2 H), 4.89 (dd, J = 6.7, 1.4 Hz, 2 H), 5.75 (dt, J = 11.7, 6.7 Hz, 1 H), 
6.64 (d, J = 11.7 Hz, 1 H), 6.89–6.93 (m, 2 H), 6.99 (d, J = 8.3 Hz, 1 H), 7.02 (d, J = 2.0 Hz, 1 H), 7.11–
7.17 (m, 2 H), 7.15 (dd, J = 8.3, 2.0 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) ! 26.4, 56.1, 62.6, 64.6, 
112.8, 116.9, 120.2, 123.8, 123.9, 130.1, 130.2, 133.0, 134.1, 144.5, 150.9, 157.4, 170.7; HRMS (ESI) 
m/z [M+Na]+ calcd for C19H20NaO5S+ 383.0924, found 383.0923. 
(14Z)-4-Methoxy-2,12-dioxa-9-thiatricyclo[14.2.2.13,7]henicosa-1(18),3(21),4,6,14,16,19-heptaen-11-
one 13. A solution of thiol 12 (31 mg, 0.09 mmol) in MeCN (1 mL) was added slowly with a syringe 
pump (15 mL/h) to a vigorously stirred solution of H2SO4 (32.0 µL, 0.60 mmol) in MeCN (30 mL) at 
0 °C. The final concentration of the mixture was ca. 3 mM. The reaction mixture was stirred for a further 
30 min at 0 °C until TLC showed full consumption of the starting material and then quenched with 
saturated aqueous NaHCO3 solution (15 mL). The mixture was concentrated under reduced pressure and 
then distributed between CH2Cl2 (20 mL) and H2O (20 mL). The aqueous phase was extracted with 
CH2Cl2 (2 " 25 mL) and the combined organic phases were washed with brine (50 mL), dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The remainder was purified by column 
chromatography (cyclohexane/ethyl acetate 7:1 ! 3:1) to yield 13 (6.7 mg, 0.02 mmol, 22%) as a white 
solid of mp 164.5–166 °C. Rf 0.46 (cyclohexane/ethyl acetate 3:1). IR (ATR) #max 2927, 2854, 1732, 
1603, 1505, 1442, 1271, 1224, 1169, 1124, 1027, 967, 841, 755 cm!1; 1H NMR (CDCl3, 500 MHz) ! 
2.82 (s, 2 H), 3.63 (s, 2 H), 3.96 (s, 3 H), 4.62 (dd, J = 5.9, 0.8 Hz, 2 H), 5.93 (d, J = 2.1 Hz, 1 H), 5.97 
(dt, J = 11.2, 5.9 Hz, 1 H), 6.83 (dd, J = 8.3, 2.1 Hz, 1 H), 6.92 (d, J = 8.3 Hz, 1 H), 6.99 (d, br, J = 11.2 
Hz, 1 H), 7.04–7.08 (m, 2 H), 7.02 (d, J = 2.0 Hz, 1 H), 7.16–7.22 (m, 2 H); 13C NMR (CDCl3, 125 
MHz) ! 30.6, 33.7, 56.2, 60.6, 113.1, 118.9, 122.2, 122.5, 125.4, 129.3, 129.9, 134.5, 136.6, 148.3, 
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149.8, 156.7, 169.6; HRMS (ESI) m/z [M+H]+ calcd for C19H19O4S+ 343.0999, found 343.0988. 
(14Z)-4-Methoxy-2,12-dioxa-9-thiatricyclo[14.2.2.13,7]henicosa-1(18),3(21),4,6,14,16,19-heptaen-11-
one 9,9-dioxide 14. A solution of thioether 13 (10 mg, 0.03 mmol) in CH2Cl2 (1.2 mL) was cooled to 
0 °C, treated with mCPBA (70–77% purity, 16.1 mg, 0.09 mmol) and stirred for 2 h at 0 °C. The 
reaction was quenched with saturated aqueous Na2SO3 solution (0.6 mL). The mixture was distributed 
between CH2Cl2 (2 mL) and H2O (2 mL) and the aqueous phase was extracted with CH2Cl2 (2 " 2 mL). 
The combined organic phases were washed with brine (5 mL), dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(cyclohexane/ethyl acetate 3:1) to yield 14 (11.0 mg, 0.03 mmol, 98%) as a white solid of mp 190–192 
°C. Rf 0.35 (cyclohexane/ethyl acetate 2:1). IR (ATR) #max 2936, 1724, 1506, 1315, 1303, 1267, 1210, 
1192, 1113, 1030, 972, 874, 825 cm!1; 1H NMR (CDCl3, 500 MHz) ! 3.41 (s, 2 H), 3.97 (s, 3 H), 4.38 
(s, 2 H), 4.66 (d, J = 6.4 Hz, 2 H), 6.07 (dt, J = 11.0, 6.4 Hz, 1 H), 6.24 (d, J = 1.8 Hz, 1 H), 6.95–7.00 
(m, 2 H, 7-H), 7.03–7.08 (m, 3 H), 7.12–7.16 (m, 2 H); 13C NMR (CDCl3, 125 MHz) ! 51.3, 56.1, 59.1, 
59.9, 113.0, 119.3, 120.6, 122.7, 125.6, 129.3, 134.2, 138.8, 150.1, 150.7, 157.1, 163.5; HRMS (ESI) 
m/z [M+H]+ calcd for C19H19O6S+ 375.0897, found 375.0888. 
3-[4-(3-Hydroxypropyl)phenoxy]-4-methoxybenzaldehyde 15. A mixture of diaryl ether (E)-9 
(2.50 g, 8.79 mmol) and a catalytic amount of PtO2 (40.0 mg, 0.18 mmol) in MeOH (75 mL) was stirred 
at room temperature under an atmosphere of hydrogen for 15 min. The reaction mixture was filtered 
through celite and the filtrate was concentrated under reduced pressure to give the crude product, which 
was purified by column chromatography (cyclohexane/ethyl acetate 1:1, Rf 0.33) to afford 15 (1.83 g, 
6.38 mmol, 73%) as a colorless oil. IR (ATR) #max 3386, 2936, 1685, 1598, 1579, 1504, 1432, 1271, 
1222, 1167, 1120, 1111, 1015, 813, 637 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.36 (s, br, 1 H), 1.84–1.94 
(m, 2 H), 2.65–2.75 (m, 2 H), 3.65–3.73 (m, 2 H), 3.97 (s, 3 H), 6.87–6.96 (m, 2 H), 7.10 (d, J = 8.4 Hz, 
1 H), 7.13–7.21 (m, 2 H), 7.40 (d, J = 2.0 Hz, 1 H), 7.63 (dd, J = 8.4 Hz, 2.0 Hz, 1 H), 9.80 (s, 1 H); 13C 
NMR (CDCl3, 125 MHz) ! 31.2, 34.2, 56.3, 62.2, 111.8, 118.4, 118.5, 127.8, 129.7, 130.1, 137.2, 146.9, 
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154.5, 156.0, 190.5; HRMS (ESI) m/z [M+H]+ calcd for C17H19O4+ 287.1278, found 287.1277. 
3-[4-(5-Formyl-2-methoxyphenoxy)phenyl]propyl 2-acetylthioacetate 16. Analogously to compound 
10, compound 16 (832 mg, 2.07 mmol, 79%) was prepared as a colorless oil from 15 (750 mg, 
2.62 mmol), S-acetylthioacetic acid37 (351 mg, 2.62 mmol), EDC (552 mg, 2.88 mmol), DMAP 
(160 mg, 1.31 mmol) and CH2Cl2 (50 mL). Rf 0.60 (cyclohexane/ethyl acetate 1:1); IR (ATR) #max 2933, 
1733, 1688, 1599, 1579, 1505, 1432, 1271, 1222, 1163, 1120, 1110, 1013, 959, 815, 625 cm!1; 1H NMR 
(CDCl3, 500 MHz) ! 1.90–2.10 (m, 2 H), 2.38 (s, 3 H), 2.60–2.73 (m, 2 H), 3.69 (s, 2 H), 3.95 (s, 3 H), 
4.15 (t, J = 6.6 Hz, 2 H), 6.88–6.95 (m, 2 H), 7.09 (d, J = 8.4 Hz, 1 H), 7.12–7.16 (m, 2 H), 7.39 (d, J = 
2.1 Hz, 1 H), 7.63 (dd, J = 8.4 Hz, 2.1 Hz, 1 H), 9.79 (s, 1 H); 13C NMR (CDCl3, 125 MHz) ! 30.0, 30.1, 
31.2, 31.4, 56.2, 65.0, 111.8, 118.3, 118.8, 127.8, 129.7, 130.0, 136.3, 146.6, 154.7, 156.0, 168.7, 190.4, 
193.8; HRMS (ESI) m/z [M+Na]+ calcd for C21H22NaO6S+ 425.1029, found 425.1026. 
3-[4-(5-Hydroxymethyl-2-methoxyphenoxy)phenyl]propyl 2-acetylthioacetate 17. Analogously to 
11, compound 17 (654 mg, 1.62 mmol, 92%) was prepared as a colorless oil from 16 (710 mg, 
1.76 mmol) and NaBH4 (33.0 mg, 0.88 mmol) in a 1:1 mixture of THF and 20% aqueous MeOH 
(24 mL). Rf 0.48 (cyclohexane/ethyl acetate 1:1); IR (ATR) #max 3499, 2939, 1733, 1694, 1505, 1425, 
1266, 1217, 1166, 1122, 1016, 959, 813, 625 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.90–1.98 (m, 2 H), 
2.37 (s, 3 H), 2.64 (t, J = 7.6 Hz, 2 H), 3.68 (s, 2 H), 3.82 (s, 3 H), 4.13 (t, J = 6.4 Hz, 2 H), 4.53 (s, br, 2 
H), 6.83–6.89 (m, 2 H), 6.92 (d, J = 2.0 Hz, 1 H), 6.95 (d, J = 8.4 Hz, 1 H), 7.05–7.12 (m, 3 H); 13C 
NMR (CDCl3, 125 MHz) ! 30.0, 30.1, 31.1, 31.4, 56.0, 64.5, 65.0, 112.4, 117.5, 119.3, 123.0, 129.4, 
133.9, 135.2, 145.3, 150.1, 155.7, 168.7, 193.9; HRMS (ESI) m/z [M+Na]+ calcd for C21H24NaO6S+ 
427.1186, found 427.1182. 
3-[4-(5-Hydroxymethyl-2-methoxyphenoxy)phenyl]propyl 2-mercaptoacetate 18. Analogously to 
12, compound 18 (1.32 g, 3.65 mmol, 92%) was prepared as a colorless oil from 17 (1.60 g, 3.95 mmol) 
and hydrazine solution (4.30 mL) in MeCN (100 mL). Rf 0.27 (cyclohexane/ethyl acetate 2:1); IR 
(ATR) #max 3427, 2936, 1729, 1505, 1442, 1424, 1267, 1217, 1167, 1122, 1022, 812 cm!1; 1H NMR 
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(CDCl3, 500 MHz) ! 1.77 (t, J = 5.6 Hz, 1 H, OH), 1.92–2.01 (m, 2 H), 2.00 (t, J = 8.3 Hz, 1 H, SH), 
2.64–2.69 (m, 2 H), 3.25 (d, J = 8.3 Hz, 2 H), 3.85 (s, 3 H), 4.15 (t, J = 6.6 Hz, 2 H), 4.56 (d, J = 5.6 Hz, 
2 H), 6.85–6.91 (m, 2 H), 6.94 (d, J = 2.1 Hz, 1 H), 6.97 (d, J = 8.2 Hz, 1 H), 7.08–7.12 (m, 3 H); 13C 
NMR (CDCl3, 125 MHz) ! 26.5, 30.1, 31.2, 56.0, 64.7, 64.9, 112.5, 117.6, 119.3, 123.1, 129.4, 133.8, 
135.2, 145.4, 150.6, 155.8, 170.9; HRMS (ESI) m/z [M+Na]+ calcd for C19H22NaO5S+ 385.1080, found 
385.1079. 
4-Methoxy-2,12-dioxa-9-thiatricyclo[14.2.2.13,7]henicosa-1(18),3(21),4,6,16,19-hexaen-11-one 19. 
Analogously to 13, compound 19 (126 mg, 0.37 mmol, 60%) was prepared from 18 (220 mg, 
0.61 mmol) and H2SO4 (227 µL, 4.25 mmol) in MeCN (200 mL). After column chromatography 
(cyclohexane/ethyl acetate 7:1) and recrystallization from n-hexane/CH2Cl2 4:1 it was obtained as 
colorless crystals of mp 126.5–127 °C. Rf 0.56 (cyclohexane/ethyl acetate 2:1); IR (ATR) #max 2934, 
2915, 2840, 1733, 1513, 1505, 1439, 1420, 1284, 1254, 1224, 1206, 1170, 1151, 1127, 1106, 1030, 988, 
973, 953, 834, 808, 705, 676, 614, cm!1; 1H NMR (CDCl3, 500 MHz) ! 2.10–2.16 (m, 2 H), 2.80 (s, 2 
H), 2.84 (t, J = 6.4 Hz, 2 H), 3.55 (s, 2 H), 3.97 (s, 3 H), 4.12–4.16 (m, 2 H), 5.86 (d, J = 2.1 Hz, 1 H), 
6.81 (dd, J = 8.2 Hz, 2.1 Hz, 1 H), 6.93 (d, J = 8.2 Hz, 1 H), 6.99–7.06 (m, 2 H), 7.24–7.29 (m, 2 H); 
13C NMR (CDCl3, 125 MHz) ! 28.4, 31.1, 33.9, 34.0, 56.2, 65.8, 113.1, 117.5, 121.6, 122.6, 129.5, 
131.0, 137.6, 147.8, 149.8, 154.7, 169.4; HRMS (ESI) m/z [M+H]+ calcd for C19H21O4S+ 345.1155, 
found 345.1161. 
4-Methoxy-2,12-dioxa-9-thiatricyclo[14.2.2.13,7]henicosa-1(18),3(21),4,6,16,19-hexaen-11-one 9,9-
dioxide 20. Analogously to 14, compound 20 was prepared from 19 (130 mg, 0.38 mmol) and mCPBA 
(70–77% purity, 287 mg, 1.66 mmol) in CH2Cl2 (30 mL). After column chromatography 
(cyclohexane/ethyl acetate 3:1) and recrystallization from n-hexane/CH2Cl2 4:1, 20 (140 mg, 
0.37 mmol, 98%) was obtained as colorless crystals of mp 207–209 °C; Rf 0.28 (cyclohexane/ethyl 
acetate 2:1). IR (ATR) #max 2971, 2931, 1724, 1506, 1460, 1312, 1304, 1265, 1250, 1214, 1196, 1161, 
1114, 1032, 972, 880, 871, 825, 818, 621 cm!1; 1H NMR (CDCl3, 500 MHz) ! 2.16–2.23 (m, 2 H), 2.85 
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(t, J = 6.6 Hz, 2 H), 3.44 (s, 2 H), 3.98 (s, 3 H), 4.21–4.27 (m, 2 H), 4.32 (s, 2 H), 6.06 (t, J = 1.1 Hz, 1 
H), 6.96–6.98 (m, 2 H), 6.98–7.02 (m, 2 H), 7.24–7.28 (m, 2 H); 13C NMR (CDCl3, 125 MHz) ! 27.4, 
33.2, 51.5, 56.1, 59.1, 65.6, 112.8, 117.6, 120.5, 122.5, 125.1, 131.3, 136.9, 149.6, 150.7, 154.9, 163.1; 
HRMS (ESI) m/z [M+Na]+ calcd for C19H20O6NaS+ 399.0873, found: 399.0878. 
(E)-3-[4-(5-Formyl-2-methoxyphenoxy)phenyl]allyl pivalate 21. A solution of alcohol (E)-9 (1.00 g, 
3.52 mmol) in CH2Cl2 (15 mL) was treated with pyridine (0.5 mL) and pivaloyl chloride (0.65 mL, 
5.28 mmol) and stirred at 40 °C for 20 h. After cooling to room temperature the organic phase was 
washed with 1M aqueous HCl (50 mL), saturated aqueous NaHCO3 (50 mL) and brine (50 ml), dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by 
column chromatography (cyclohexane/ethyl acetate 9:1) to yield 21 (0.97 g, 75% ) as a yellowish oil; Rf 
0.29 (cyclohexane/ethyl acetate 3:1). IR (ATR) #max 2969, 1722, 1688, 1599, 1579, 1505, 1433, 1274, 
1224, 1147, 1119, 1019, 960, 812, 769, 636 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.23 (s, 9 H), 3.94 (s, 3 
H), 4.71 (dd, J = 6.4, 1.1 Hz, 2 H), 6.20 (dt, J = 15.9, 6.3 Hz, 1 H), 6.61 (d, br, J = 15.9 Hz, 1 H), 6.89–
6.95 (m, 2 H), 7.11 (d, J = 8.4 Hz, 1 H), 7.33–7.38 (m, 2 H), 7.46 (d, J = 1.9 Hz, 1 H), 7.67 (dd, J = 8.4, 
1.9 Hz, 1 H), 9.82 (s, 1 H); 13C NMR (CDCl3, 125 MHz) ! 27.2, 38.8, 56.3, 65.0, 112.1, 118.1, 119.7, 
122.8, 128.1, 128.2, 130.2, 131.8, 132.9, 146.1, 156.3, 156.7, 178.3, 190.3; HRMS (ESI) m/z [M+Na]+ 
calcd for C22H24O5Na+ 391.1516, found 391.1509. 
(2R,3R)-3-[4-(5-Formyl-2-methoxyphenoxy)phenyl]-2,3-dihydroxypropyl pivalate 22. A mixture of 
AD-mix-# (3.43 g, 1.4 g/mmol) and methanesulfonamide (233 mg, 95.0 mg/mmol) were suspended at 
room temperature in a H2O/tBuOH mixture (1:1, 30.6 mL). After cooling to 0 °C the olefin 21 (902 mg, 
2.45 mmol) was added and the mixture was stirred vigorously for 2 d at 3 °C. The reaction was cooled 
again to 0 °C, Na2SO3 (3.7 g, 1.5 g/mmol) was added, and stirring was continued for 30 min. The phases 
were separated, and the aqueous one was acidified with saturated NH4Cl solution (50 mL) and extracted 
with ethyl acetate (3 " 50 mL). The combined organic layers were washed with brine (100 mL), dried 
over Na2SO4 and concentrated under reduced pressure. The crude product was purified by column 
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chromatography (cyclohexane/ethyl acetate 1:1, Rf 0.20) to yield 22 (575 mg, 1.44 mmol, 59%) as a 
yellowish oil; [$]23D –9.4 (c 1.00, acetone), ee > 99%; IR (ATR) #max 3481, 2970, 1727, 1690, 1600, 
1507, 1435, 1397, 1277, 1225, 1161, 1121, 1023, 816 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.19 (s, 9 H), 
3.14 (s, br, 2 " OH), 3.85–3.95 (m, 2 H), 3.90 (s, 3 H), 4.14 (dd, J = 11.6, 3.5 Hz, 1 H), 4.60 (d, J = 6.4 
Hz, 1 H), 6.90–6.94 (m, 2 H), 7.09 (d, J = 8.4 Hz, 1 H), 7.27–7.31 (m, 2 H), 7.44 (d, J = 2.0 Hz, 1 H), 
7.65 (dd, J = 8.4, 2.0 Hz, 1 H), 9.77 (s, 1 H); 13C NMR (CDCl3, 125 MHz) ! 27.1, 38.8, 56.2, 65.0, 73.8, 
74.1, 112.1, 117.7, 120.0, 128.1, 128.3, 130.0, 135.1, 145.7, 156.4, 156.8, 178.8, 190.5; HRMS (ESI) 
m/z [M+Na]+ calcd for C22H26O7Na+ 425.1571, found 425.1568. 
(2R,3R)-3-[4-(5-Formyl-2-methoxyphenoxy)phenyl]-2,3-bis(triisopropylsilyloxy)propyl pivalate 23. 
A solution of diol 22 (4.00 g, 9.94 mmol) and 2,6-lutidine (5.05 mL, 34.8 mmol) in DMF (100 mL) was 
slowly treated with TIPS-OTf (8.00 mL, 29.8 mmol) at 0 °C and then stirred at 60 °C for 27 h. The 
reaction was quenched with saturated aqueous NH4Cl solution (50 mL), the aqueous layer was extracted 
twice with diethyl ether (50 mL), and the combined organic phases were washed with H2O (100 mL) 
and brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue 
was purified by column chromatography (cyclohexane/ethyl acetate 9:1) to obtain 23 (6.96 g, 
9.73 mmol, 98%) as a colorless oil; Rf 0.43 (cyclohexane/ethyl acetate 3:1); [$]23D +3.7 (c 0.50, CHCl3); 
IR (ATR) #max 2945, 2867, 1729, 1696, 1600, 1581, 1505, 1463, 1433, 1276, 1224, 1153, 1120, 1091, 
1067, 1014, 996, 882, 844, 680 cm!1; 1H NMR (CDCl3, 500 MHz) ! 0.99–1.09 (m, 42 H), 1.16 (s, 9 H), 
3.70 (dd, J = 11.6, 5.6 Hz, 1 H), 3.94 (s, 3 H), 4.20–4.25 (m, 1 H), 4.38 (dd, J = 11.6, 3.4 Hz, 1 H), 4.94 
(d, J = 4.2 Hz, 1 H), 6.88–6.92 (m, 2 H), 7.10 (d, J = 8.4 Hz, 1 H), 7.35–7.39 (m, 2 H), 7.43 (d, J = 2.0 
Hz, 1 H), 7.66 (dd, J = 8.4, 2.0 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) ! 12.4, 12.8, 17.95, 18.0, 18.1, 
18.2, 27.2, 38.7, 56.2, 66.4, 74.9, 75.1, 112.1, 117.1, 120.0, 127.3, 128.7, 130.2, 136.1, 146.5, 156.0, 
156.2, 178.5, 190.3; HRMS (ESI) m/z [M+Na]+ calcd for C40H66O7NaSi2+ 737.4239, found 737.4231. 
(2R,3R)-3-[4-(5-Hydroxymethyl-2-methoxyphenoxy)phenyl]-2,3-bis(triisopropylsilyl)oxypropan-1-
ol 24. Analogously to 8, alcohol 24 (5.42 g, 8.56 mmol, 94%) was prepared as a colorless oil from 23 
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(6.50 g, 9.09 mmol) and DIBAL-H (1M in hexane, 29.1 mL, 29.1 mmol) in CH2Cl2 (120 mL). Rf 0.44 
(cyclohexane/ethyl acetate 2:1); [$]23D +19.0 (c 1.0, CHCl3); IR (ATR) #max 3410, 2944, 2865, 1608, 
1505, 1463, 1426, 1270, 1222, 1121, 1058, 1031, 1013, 945, 881, 845, 773, 679, 655 cm!1; 1H NMR 
(CDCl3, 500 MHz) ! 0.96–1.10 (m, 42 H), 1.94 (s, br, 1 H, OH), 2.89 (dd, J = 8.3, 1.7 Hz, 1H, OH), 
3.45 (ddd, J = 11.0, 8.3, 4.2, 1 H), 3.57 (ddd, J = 11.0, 8.0, 1.7, 1 H), 3.80 (s, 3 H), 4.23 (dt, J = 8.0, 4.2 
Hz, 1 H), 4.54 (d, br, J = 2.4 Hz, 1 H), 5.04 (d, J = 4.2 Hz, 1 H), 6.88–6.92 (m, 2 H), 6.94 (d, J = 2.1 Hz, 
1 H), 6.95 (d, J = 8.3 Hz, 1 H), 7.09 (dd, J = 8.3, 2.0 Hz, 1 H), 7.31–7.36 (m, 2 H); 13C NMR (CDCl3, 
125 MHz) ! 12.1, 12.5, 17.8, 17.9, 18.0, 18.1, 55.9, 63.5, 64.6, 73.3, 77.8, 112.6, 116.6, 119.2, 122.9, 
128.7, 133.85, 133.9, 145.5, 150.5, 156.9; HRMS (ESI) m/z [M+Na]+ calcd for C35H60O6NaSi2+ 
655.3821, found 655.3819. 
(2R,3R)-3-[4-(5-Formyl-2-methoxyphenoxy)phenyl]-2,3-bis(triisopropylsilyloxy)propan-1-ol 25. A 
mixture of diol 24 (5.39 g, 8.51 mmol), activated MnO2 (22.2 g, 0.26 mol), and CHCl3 (110 mL) was 
stirred at room temperature for 17 h, and then filtered through celite. The combined filtrate and 
washings with CH2Cl2 were concentrated under reduced pressure to give the crude product which was 
purified by column chromatography (cyclohexane/ethyl acetate 4:1) to afford 25 (5.33 g, 8.45 mmol, 
99%) as a colorless oil; Rf 0.64 (cyclohexane/ethyl acetate 3:1); [$]23D –21.4 (c 1.0, CHCl3); IR (ATR) 
#max 2944, 2863, 1694, 1600, 1581, 1505, 1463, 1433, 1274, 1224, 1111, 1059, 1014, 997, 881, 847, 
679, 654 cm!1; 1H NMR (CDCl3, 500 MHz) ! 0.95–1.14 (m, 42 H), 2.86 (s, br, 1 H, OH), 3.46 (dd, J = 
10.9, 4.0 Hz, 1 H), 3.58 (dd, J = 10.9, 7.9 Hz, 1 H), 3.92 (s, 3 H), 4.24 (dt, J = 7.9, 4.3 Hz, 1 H), 5.06 (d, 
J = 4.3 Hz, 1 H), 6.90–6.96 (m, 2 H), 7.09 (d, J = 8.4 Hz, 1 H), 7.34–7.39 (m, 2 H), 7.42 (d, J = 2.0 Hz, 
1 H), 7.65 (dd, J = 8.4, 2.0 Hz, 1 H), 9.80 (s, 1 H); 13C NMR (CDCl3, 125 MHz) ! 12.1, 12.5, 17.85, 
17.9, 18.0, 18.1, 56.1, 63.6, 73.3, 77.7, 112.0, 117.2, 119.5, 127.5, 129.0, 130.1, 134.8, 146.5, 156.0, 
156.1, 190.2; HRMS (ESI) m/z [M+Na]+ calcd for C35H58O6NaSi2+ 653.3664, found 653.3661.  
(2R,3R)-3-[4-(5-Formyl-2-methoxyphenoxy)phenyl]-2,3-bis(triisopropylsilyloxy)propyl 2-
acetylthioacetate 26. Analogously to 10, compound 26 was prepared from 25 (0.40 g, 3.25 mmol), S-
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acethylthioacetic acid37 (0.96 g, 7.15 mmol), EDC (1.37 g, 7.15 mmol) and DMAP (160 mg, 
1.31 mmol) in CH2Cl2 (130 mL). After column chromatography (cyclohexane/ethyl acetate 6:1) 26 
(3.79 g, 5.08 mmol, 78%) was obtained as a colorless oil; Rf 0.41 (cyclohexane/ethyl acetate 3:1); [$]23D 
+2.9 (c 0.5, CHCl3); IR (ATR) #max 2944, 2865, 1743, 1694, 1600, 1581, 1505, 1463, 1433, 1275, 1224, 
1120, 1067, 1013, 960, 881, 844, 680, 624 cm!1; 1H NMR (CDCl3, 500 MHz) ! 0.96–1.12 (m, 42 H), 
2.36 (s, 3 H), 3.59–3.69 (m, 2 H), 3.71 (dd, J = 11.3, 7.1 Hz, 1 H), 3.92 (s, 3 H), 4.27 (ddd, J = 7.1, 4.2, 
3.0 Hz, 1 H), 4.44 (dd, J = 11.3, 3.0 Hz, 1 H), 4.94 (d, J = 4.3 Hz, 1 H), 6.86–6.92 (m, 2 H), 7.09 (d, J = 
8.4 Hz, 1 H), 7.33–7.37 (m, 2 H), 7.43 (d, J = 2.0 Hz, 1 H), 7.65 (dd, J = 8.4, 2.0 Hz, 1 H), 9.80 (s, 1 H); 
13C NMR (CDCl3, 125 MHz) ! 12.2, 12.7, 17.9, 17.95, 18.0, 18.1, 30.0, 31.3, 56.1, 67.4, 74.2, 75.2, 
112.0, 117.0, 120.0, 127.4, 128.6, 130.1, 135.3, 146.3, 156.1, 156.2, 168.5, 190.2, 193.4; HRMS (ESI) 
m/z [M+Na]+ calcd for C39H62O8NaSSi2+ 769.3596, found 769.3592. 
(2R,3R)-3-[4-(5-Hydroxymethyl-2-methoxyphenoxy)phenyl]-2,3-bis(triisopropylsilyloxy)propyl 2-
acetylthioacetate 27. Analogously to 11, compound 27 was prepared from 26 (3.59 g, 4.80 mmol) and 
NaBH4 (91.0 mg, 2.40 mmol) in a 1:1 mixture of THF and 20% aqueous MeOH (66 mL). After column 
chromatography (cyclohexane/ethyl acetate 5:1) 27 (3.57 g, 4.77 mmol, 99%) was obtained as a 
colorless oil; Rf 0.27 (cyclohexane/ethyl acetate 3:1); [$]23D +0.5 (c 1.0, CHCl3); IR (ATR) #max 3413, 
2943, 2865, 1743, 1702, 1608, 1505, 1463, 1426, 1270, 1222, 1123, 1092, 1067, 1012, 881, 844, 680, 
624 cm!1; 1H NMR (CDCl3, 500 MHz) ! 0.97–1.11 (m, 42 H), 1.62 (t, J = 5.8 Hz, 1 H, OH), 2.37 (s, 3 
H), 3.59–3.69 (m, 2 H), 3.71 (dd, J = 11.3, 7.1 Hz, 1 H), 3.83 (s, 3 H), 4.26 (ddd, J = 7.1, 4.2, 2.9 Hz, 1 
H), 4.42 (dd, J = 11.3, 2.9 Hz, 1 H), 4.57 (d, J = 5.8 Hz, 2 H), 4.93 (d, J = 4.3 Hz, 1 H), 6.85–6.90 (m, 2 
H), 6.95 (d, J = 2.1 Hz, 1 H), 6.97 (d, J = 8.3 Hz, 1 H), 7.11 (dd, J = 8.3, 2.1 Hz, 1 H), 7.30–7.34 (m, 2 
H); 13C NMR (CDCl3, 125 MHz) ! 12.3, 12.7, 17.95, 18.0, 18.1, 18.2, 30.1, 31.4, 56.0, 64.8, 67.5, 74.3, 
75.3, 112.7, 116.7, 119.4, 123.0, 128.4, 133.9, 134.6, 145.6, 150.7, 156.8, 168.6, 193.5; HRMS (ESI) 
m/z [M+Na]+ calcd for C39H64O8NaSSi2+ 771.3753, found 771.3749.  
(2R,3R)-3-[4-(5-Hydroxymethyl-2-methoxyphenoxy)phenyl]-2,3-bis(triisopropylsilyloxy)propyl 2-
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mercaptoacetate 28. Analogously to 12, compound 28 was prepared from 27 (4.22 g, 5.63 mmol) and 
hydrazine solution (6.10 mL) in MeCN (158 mL). After column chromatography (cyclohexane/ethyl 
acetate 3:1), 28 (3.73 g, 5.27 mmol, 94%) was obtained as a colorless oil; Rf 0.27 (cyclohexane/ethyl 
acetate 3:1); [$]23D +2.6 (c 1.0, CHCl3); IR (ATR) #max 2944, 2866, 1740, 1505, 1463, 1425, 1270, 1221, 
1122, 1091, 1066, 1012, 881, 844, 754, 680 cm!1; 1H NMR (CDCl3, 500 MHz) !  0.97–1.10 (m, 42 H), 
1.57 (s, br, 1 H, OH), 1.94 (t, J = 8.2 Hz, 1 H, SH), 3.17 (dd, J = 8.2, 4.6 Hz, 2 H), 3.71 (dd, J = 11.3, 
7.1 Hz, 1 H), 3.83 (s, 3 H), 4.27 (ddd, J = 7.1, 4.3, 2.8 Hz, 1 H), 4.43 (dd, J = 11.3, 2.8 Hz, 1 H), 4.58 (s, 
2 H), 4.93 (d, J = 4.3 Hz, 1 H), 6.86–6.90 (m, 2 H), 6.95 (d, J = 2.1 Hz, 1 H), 6.98 (d, J = 8.3 Hz, 1 H), 
7.11 (dd, J = 8.3, 2.1 Hz, 1 H), 7.30–7.34 (m, 2 H); 13C NMR (CDCl3, 125 MHz) ! 12.2, 12.7, 17.95, 
18.0, 18.1, 18.2, 26.4, 56.0, 64.8, 67.3, 74.3, 75.3, 112.6, 116.6, 119.4, 123.0, 128.4, 133.9, 134.5, 
145.5, 150.7, 156.8, 170.8; HRMS (ESI) m/z [M+Na]+ calcd for C37H62O7NaSSi2+ 729.3647, found 
729.3635. 
(14R,15R)-4-Methoxy-14,15-bis[(triisopropylsilyl)oxy]-2,12-dioxa-9-thiatricyclo-
[14.2.2.13,7]henicosa-1(18),3(21),4,6,16,19-hexaen-11-one 29. A solution of thiol 28 (1.88 g, 
2.66 mmol) in toluene (887 mL) was treated with SO3 • pyridine (423 mg, 2.66 mmol) and stirred for 
2 h at 110 °C under reflux. The mixture was allowed to cool to room temperature and then concentrated 
under reduced pressure. The residue was purified by column chromatography (cyclohexane/ethyl acetate 
30:1, Rf 0.27) followed by crystallization from hexane/CH2Cl2 to yield 29 (780 mg, 1.13 mmol, 43%) as 
a colorless waxy solid; [$]23D +19.3 (c 1.0, CHCl3); IR (ATR) #max 2947, 2865, 1736, 1504, 1265, 1215, 
1124, 1087, 1066, 1013, 881, 681 cm!1; 1H NMR (CDCl3, 500 MHz) ! 1.01–1.12 (m, 42 H), 2.78 (d, J = 
2.3 Hz, 2 H), 3.49 (d, J = 4.0 Hz, 2 H), 3.97 (s, 3 H), 4.15–4.26 (m, 3 H), 5.00 (d, J = 4.2 Hz, 1 H), 6.03 
(d, J = 2.1 Hz, 1 H), 6.80 (dd, J = 8.3, 2.1 Hz, 1 H), 6.93 (d, J = 8.3 Hz, 1 H), 7.01 (dd, J = 8.2, 2.4 Hz, 
1 H), 7.04 (dd, J = 8.4, 2.4 Hz, 1 H), 7.45 (dd, J = 8.2, 2.2 Hz, 1 H), 7.64 (dd, J = 8.4, 2.2 Hz, 1 H); 13C 
NMR (CDCl3, 125 MHz) ! 12.4, 12.5, 18.05, 18.1, 18.2, 31.8, 34.1, 56.2, 63.3, 74.3, 75.7, 113.1, 117.4, 
120.9, 121.5, 122.4, 127.8, 129.4, 129.5, 137.9, 147.9, 149.6, 155.7, 169.5; HRMS (ESI) m/z [M+Na]+ 
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calcd for C37H60O6NaSSi2+ 711.3541, found 711.3526. 
(14R,15R)-4-Methoxy-14,15-bis(triisopropylsilyloxy)-2,12-dioxa-9-thiatricyclo-
[14.2.2.13,7]henicosa-1(18),3(21),4,6,16,19-hexaen-11-one 9,9-dioxide 30. Analogously to 14, 
compound 30 was prepared from 29 (440 mg, 0.64 mmol) and mCPBA (353 mg, 2.04 mmol) in CH2Cl2 
(25 mL). After column chromatography (cyclohexane/ethyl acetate 5:1) and recrystallization from 
hexane/CH2Cl2 4:1, 30 (384 mg, 0.53 mmol, 83%) was obtained as colorless crystals of mp 176–178 °C; 
Rf 0.18 (cyclohexane/ethyl acetate 8:1); [$]23D –23.3 (c 1.0, CHCl3); IR (ATR) #max 2942, 2865, 1738, 
1519, 1462, 1318, 1268, 1214, 1126, 1110, 1089, 1066, 1014, 882, 858, 680, 654 cm!1; 1H NMR 
(CDCl3, 500 MHz) ! 0.99–1.14 (m, 42 H), 3.34 (dd, J = 17.5, 1.5 Hz, 1 H), 3.47 (d, J = 17.5 Hz, 1 H), 
3.98 (s, 3 H), 4.05 (dd, J = 11.9, 6.4 Hz, 1 H), 4.17 (dd, J = 14.3, 1.5 Hz, 1 H), 4.27 (dd, J = 6.4, 4.5 Hz, 
1 H), 4.29 (d, J = 11.9 Hz, 1 H), 4.37 (d, J = 14.3 Hz, 1 H), 4.96 (d, J = 4.5 Hz, 1 H), 6.16 (s, br, 1 H), 
6.95–6.99 (m, 2 H), 6.97 (dd, J = 8.3, 2.6 Hz, 1 H), 7.09 (dd, J = 8.4, 2.6 Hz, 1 H), 7.49 (dd, J = 8.3, 2.1 
Hz, 1 H), 7.65 (dd, J = 8.4, 2.1 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) ! 12.6, 12.65, 18.0, 18.05, 18.1, 
18.2, 51.4, 56.1, 59.2, 64.1, 74.8, 76.7, 112.9, 117.3, 120.4, 121.1, 122.8, 125.1, 128.3, 129.7, 137.8, 
149.6, 150.3, 155.7, 162.6; HRMS (ESI) m/z [M+Na]+ calcd for C37H60O8NaSSi2+ 743.3440, found 
743.3420. 
11-O-Methylcorniculatolide A 31. Sulfone 20 (200 mg, 0.53 mmol) was subjected to flash vacuum 
pyrolysis at 600 °C and 5 " 10–2 Torr. The crude product was purified by column chromatography 
(cyclohexane/ethyl acetate 6:1) to yield 31 (88 mg, 0.26 mmol, 53%) as a white solid of mp 141–143 °C 
[lit.11 142–145 °C]; Rf 0.44 (cyclohexane/ethyl acetate 3:1); IR (ATR) #max 2925, 1727, 1586, 1516, 
1505, 1465, 1435, 1414, 1358, 1263, 1212, 1149, 1127, 1029, 1008, 978, 906, 891, 867, 830, 799, 727, 
701 cm!1; 1H NMR (CDCl3, 500 MHz) ! 2.06–2.13 (m, 2 H), 2.23–2.28 (m, 2 H), 2.81 (t, J = 6.6 Hz, 2 
H), 2.83–2.87 (m, 2 H), 3.95 (s, 3 H), 4.05–4.10 (m, 2 H), 5.34 (d, J = 2.1 Hz, 1 H), 6.63–6.67 (m, 1 H), 
6.81 (d, J = 8.2 Hz, 1 H), 7.01–7.06 (m, 2 H), 7.27–7.32  (m, 2 H); 13C NMR (CDCl3, 125 MHz) ! 26.9, 
28.6, 32.7, 34.0, 56.2, 64.0, 111.8, 113.3, 120.8, 123.6, 131.0, 133.2, 137.4, 146.1, 151.2, 154.5, 173.8; 
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HRMS (ESI) m/z [M+H]+ calcd for C19H21O4+ 313.1434, found 313.1433.  
Combretastatin D-4 5. A mixture of anhydrous AlCl3 (75.0 mg, 0.56 mmol) and ethanethiol 
(0.52 mL, 7.04 mmol) in CH2Cl2 (3.5 mL) was cooled to !17 °C and treated with 11-O-
methylcorniculatolide A 31 (22.0 mg, 0.07 mmol). The mixture was stirred at !17 °C for ca 1 h until 
TLC indicated consumption of the starting material. Water (5 mL) was added, the layers were separated, 
and the aqueous one was extracted with CH2Cl2 (2 " 5 mL). The combined organic phases were washed 
with brine (15 mL), dried over Na2SO2, and concentrated under reduced pressure. The remainder was 
purified by column chromatography (cyclohexane/ethyl acetate 3:1, Rf 0.32) followed by crystallization 
from hexane/acetone 4:1 to yield 5 (20.0 mg, 0.07 mmol, 96%) as colorless crystals of mp 153–156 °C 
[lit.10 155.4–156.3 °C]; IR (ATR) #max 3416, 2938, 1701, 1595, 1518, 1504, 1448, 1359, 1243, 1219, 
1190, 1160, 1115, 942, 912, 870, 884, 805, 602 cm!1; 1H NMR (CDCl3, 500 MHz) ! 2.07–2.12 (m, 2 
H), 2.24–2.27 (m, 2 H), 2.79–2.85 (m, 4 H), 4.04–4.08 (m, 2 H), 5.29 (d, J = 2.1 Hz, 1 H), 5.50 (s, br, 1 
H, OH), 6.60 (dd, J = 8.1, 2.1, Hz, 1 H), 6.83 (d, J = 8.1 Hz, 1 H), 6.99–7.04 (m, 2 H), 7.29–7.32  (m, 2 
H); 13C NMR (CDCl3, 125 MHz) ! 27.0, 28.7, 32.7, 34.0, 63.9, 112.6, 114.9, 121.5, 123.5, 131.1, 132.6, 
137.9, 142.5, 149.0, 154.2, 173.9; HRMS (ESI) m/z [M!H+Na]+ calcd for C18H17NaO4+ 320.1019, found 
320.1017. 
(13R,14R)-4-Methoxy-13,14-bis(triisopropylsilyl)oxy-2,11-dioxatricyclo-[13.2.2.13,7]icosa-
1(17),3(20),4,6,15,18-hexaen-10-one 32. Analogously to 31, compound 32 was prepared by FVP of 
sulfone 30 (700 mg, 0.97 mmol). The crude product was purified by column chromatography 
(cyclohexane/ethyl acetate 40:1) to yield 32 (158 mg, 0.24 mmol, 25%) as a colorless waxy solid; Rf 
0.44 (cyclohexane/ethyl acetate 3:1). [$]23D –5.0 (c 0.2, CHCl3); IR (ATR) #max 2944, 2867, 1737, 1519, 
1504, 1463, 1264, 1216, 1127, 1089, 1067, 1014, 993, 882, 799, 755, 733, 680 cm!1; 1H NMR (CDCl3, 
500 MHz) ! 1.02–1.14 (m, 42 H), 2.18–2.34 (m, 2 H), 2.72 (dd, J = 17.0, 8.2 Hz, 1 H), 2.97 (dd, J = 
17.0, 10.3 Hz, 1 H), 3.85 (dd, J = 12.1, 6.6 Hz, 1 H), 3.94 (s, 3 H), 4.22–4.27 (m, 2 H), 4.96 (d, J = 4.3 
Hz, 1 H), 5.41 (d, J = 2.0 Hz, 1 H), 6.65 (dd, J = 8.2, 2.0 Hz, 1 H), 6.81 (d, J = 8.2 Hz, 1 H), 7.01–7.04 
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(m, 2 H), 7.42–7.45 (m, 1 H), 7.66–7.70 (m, 1 H); 13C NMR (CDCl3, 125 MHz) ! 12.5, 12.55, 18.1, 
18.15, 26.9, 32.7, 56.3, 63.1, 74.5, 76.5, 111.9, 113.6, 120.7, 122.0, 123.5, 127.8, 128.9, 133.0, 137.6, 
146.1, 151.2, 155.8, 173.9; HRMS (ESI) m/z [M+Na]+ calcd for C37H60NaO6Si2+ 679.3821, found 
679.3811. 
(13R,14R)-13,14-Dihydroxy-4-methoxy-2,11-dioxatricyclo[13.2.2.13,7]icosa-1(17),3(20),4,6,15,18-
hexaen-10-one 33. A solution of silyl ether 32 (73.0 mg, 0.11 mmol) in THF (5 mL) was treated with 
48% aqueous HF (23.0 µL, 1.33 mmol). The mixture was stirred at room temperature for 24 h, then 
further HF (23.0 µL, 1.33 mmol) was added and the mixture was stirred for another 3 d at room 
temperature. The reaction was terminated by addition of saturated aqueous NaHCO3 solution (3 mL). 
The layers were separated and the aqueous phase was extracted with ethyl acetate (3 " 10 mL). The 
combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The crude 
product was taken up in THF (1 mL) and treated once more with HF (50 µL, 2.87  mmol) for 7 d at 
room temperature. The identical workup gave a crude product which was purified by column 
chromatography (cyclohexane/ethyl acetate 1:2, Rf 0.36) to afford 33 (20.0 mg, 0.06 mmol, 53%) as a 
white solid of mp 222–225 °C. [$]23D –35 (c 1.0, CHCl3); IR (ATR) #max 3522, 3401, 2956, 2919, 1720, 
1589, 1517, 1504, 1460, 1435, 1413, 1343, 1270, 1215, 1163, 1147, 1126, 1109, 1098, 1037, 1016, 995, 
976, 954, 910, 878, 848, 803 cm!1; 1H NMR (MeOD, 500 MHz) ! 2.11 (ddd, J = 17.0, 11.8, 1.2 Hz, 1 
H), 2.45 (ddd, J = 17.0, 7.2, 1.2 Hz, 1 H), 2.59 (dd, J = 16.6, 7.2 Hz, 1 H), 2.98 (ddd, J = 16.6, 11.8, 0.8 
Hz, 1 H), 3.59 (d, J = 11.8 Hz, 1 H), 3.82 (t, J = 7.6 Hz, 1 H), 3.89 (s, 3 H), 4.26 (dd, J = 11.8, 7.6 Hz, 1 
H), 4.50 (d, J = 8.0 Hz, 1 H), 5.30 (d, J = 2.1 Hz, 1 H), 6.67 (dd, J = 8.2, 2.1 Hz, 1 H), 6.89 (d, J = 8.2 
Hz, 1 H), 6.94 (dd, J = 8.2, 2.4 Hz, 1 H), 7.12 (dd, J = 8.5, 2.4 Hz, 1 H), 7.29 (dd, J = 8.2, 2.2 Hz, 1 H), 
7.65 (dd, J = 8.5, 2.2 Hz, 1 H); 13C NMR (MeOD, 125 MHz) ! 27.9, 33.5, 57.0, 68.8, 76.6, 79.5, 114.0, 
114.7, 122.4, 124.1, 125.2, 130.1, 131.4, 134.7, 139.1, 147.8, 152.7, 157.9, 175.0; HRMS (ESI) m/z 
[M!H2O+H]+ calcd for C19H19O5+ 327.1227, found 327.1224. 
Methylcombretastatin D-2 34 and (11Z)-4-methoxy-2-oxatricyclo[11.2.2.13,7]octadeca-1(15), 
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3(18),4,6,11,13,16-heptaene 35. Analogously to the synthesis of 31, sulfone 14 (150 mg, 0.40 mmol) 
was submitted to a FVP. The crude product was purified and separated by column chromatography 
(cyclohexane/ethyl acetate 40:1) to yield 34 (25 mg, 0.08 mmol, 20%) as white solid of mp 131–133 °C 
[lit.12 130–132 °C] and 35 (6 mg, 0.03 mmol, 6%), which was obtained as colorless crystals of mp 122–
124 °C after crystallization from pentane/hexane 3:1.  
Compound 34: Rf 0.30 (cyclohexane/ethyl acetate 5:1); IR (ATR) #max 2961, 2908, 1729, 1583, 1519, 
1502, 1464, 1433, 1376, 1345, 1264, 1217, 1149, 1127, 1029, 978, 904, 869, 837, 803, 737 cm-1; 1H 
NMR (CDCl3, 500 MHz) ! 2.27–2.31 (m, 2 H), 2.87–2.91 (m, 2 H), 3.95 (s, 3 H), 4.66 (d, J = 6.8 Hz, 2 
H), 5.11 (d, J = 2.1 Hz, 1 H), 6.05 (dt, J = 11.0, 6.8 Hz, 1 H), 6.66–6.70 (m, 1 H), 6.83 (d, J = 8.3 Hz, 1 
H), 7.08–7.13 (m, 3 H), 7.29–7.33 (m, 2 H); 13C NMR (CDCl3, 125 MHz) ! 26.6, 31.2, 59.0, 59.2, 
112.1, 113.2, 121.2, 123.9, 125.4, 128.9, 132.3, 135.0, 137.8, 146.0, 151.3, 155.9, 173.2; HRMS (ESI) 
m/z [M+H]+ calcd for C19H19O4+ 311.1278, found 311.1275. 
Compound 35: Rf 0.66 (cyclohexane/ethyl acetate 5:1); IR (ATR) #max 2928, 1578, 1517, 1491, 1461, 
1408, 1258, 1212, 1191, 1149, 1123, 1091, 1029, 962, 918, 869, 831, 791, 730, 717 cm!1; 1H NMR 
(CDCl3, 500 MHz) ! 1.22–1.29 (m, 2 H), 1.71–1.82 (m, 2 H), 2.37–2.45 (m, 2 H), 3.93 (s, 3 H), 4.08 (d, 
J = 2.1 Hz, 1 H), 5.87 (dt, J = 10.9, 8.2 Hz, 1 H), 6.53–6.57 (m, 1 H), 6.74 (d, J = 8.2 Hz, 1 H), 6.93 (d, 
J = 10.9 Hz, 1 H), 7.21–7.26 (m, 4 H); 13C NMR (CDCl3, 125 MHz) ! 26.1, 26.3, 30.3, 56.3, 112.0, 
115.6, 121.5, 126.0, 130.6, 131.4, 133.1, 134.8, 136.4, 145.2, 153.8, 160.4; HRMS (ESI) m/z [M+H]+ 
calcd for C18H19O2+ 267.1380, found 267.1372.   
Crystal data: C18H18O2, M=1052.36, monoclinic, space group P21/c, a=8.4129(17), b=18.533(4), 
c=9.925(2) Å, $=%=90°, &=112.62(3)°, V=1428.4(5) Å3, Z=4, '=0.71073 Å, µ=0.079 mm–1, T=293(2) 
K; 10498 reflections measured, 2652 unique; final refinement to convergence on F2 gave R=0.0540 and 
Rw=0.0990, GOF=0.608. CCDC 1505171. 
Combretastatin D-2 4. Analogously to 5, compound 4 was prepared from 34 (11.0 mg, 35.4 µmol), 
anhydrous AlCl3 (37.0 mg, 0.28 mmol) and ethanethiol (0.26 mL, 3.54 mmol) in CH2Cl2 (1.48 mL). 
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After column chromatography (cyclohexane/ethyl acetate 5:1, Rf 0.27) followed by crystallization from 
hexane/acetone 4:1, 4 (7.0 mg, 23.6 µmol, 67%) was obtained as colorless crystals of mp 152–154 °C 
[lit.7b 148-151 °C]. IR (ATR) #max 3426, 2923, 2854, 1730, 1594, 1519, 1503, 1439, 1376, 1283, 1215, 
1159, 1111, 978, 869, 807, 729 cm!1; 1H NMR (CDCl3, 500 MHz) ! 2.27–2.31 (m, 2 H), 2.85–2.89 (m, 
2 H), 4.64 (d, J = 6.8 Hz, 2 H), 5.06 (d, J = 2.0 Hz, 1 H), 5,46 (s, br, 1 H, OH), 6.06 (dt, J = 11.1, 6.8 
Hz, 1 H), 6.63 (dd, J = 8.2, 2.0 Hz, 1 H), 6.85 (d, J = 8.2 Hz, 1 H), 7.08–7.13 (m, 3 H), 7.31–7.34 (m, 2 
H); 13C NMR (CDCl3, 125 MHz) ! 26.8, 31.3, 59.0, 112.4, 115.3, 121.8, 123.9, 125.6, 129.0, 131.9, 
135.5, 137.7, 142.5, 148.6, 155.5, 173.3; HRMS (ESI) m/z [M+H]+ calcd for C18H17O4+ 297.1121, found 
297.1113. 
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